ESIDRIX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ESIDRIX (ESIDRIX).
Thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption, leading to increased diuresis and decreased extracellular volume.
| Metabolism | Not significantly metabolized; primarily excreted unchanged in urine. |
| Excretion | Renal: approximately 70% excreted unchanged in urine; biliary/fecal: less than 10%. |
| Half-life | Terminal elimination half-life is approximately 10-15 hours (mean 12 hours); clinical context: half-life prolonged in renal impairment, requiring dose adjustment. |
| Protein binding | Approximately 75% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd is 0.1-0.2 L/kg; indicates limited extravascular distribution consistent with hydrophilic properties. |
| Bioavailability | Oral: bioavailability is approximately 80-90%. |
| Onset of Action | Oral: diuresis begins within 1-2 hours; peak effect at 2-4 hours. |
| Duration of Action | Oral: diuretic effect lasts approximately 6-12 hours; antihypertensive effect persists for 24 hours with once-daily dosing. |
25-50 mg orally once daily; may increase to 100 mg once daily or 50 mg twice daily for resistant edema.
| Dosage form | TABLET |
| Renal impairment | GFR 25-50 mL/min: administer every 12 hours; GFR 10-25 mL/min: administer every 24 hours; GFR <10 mL/min: not recommended due to ineffectiveness. |
| Liver impairment | Child-Pugh Class B or C: reduce dose by 50% or use with caution due to risk of electrolyte disturbances and hepatic encephalopathy. |
| Pediatric use | 1-2 mg/kg orally once daily; maximum 50 mg/day. |
| Geriatric use | Start at 12.5-25 mg orally once daily; monitor electrolytes and renal function; adjust dose based on response and tolerability. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ESIDRIX (ESIDRIX).
| Breastfeeding | Excreted in human milk; M/P ratio unknown. Due to potential for adverse effects (e.g., electrolyte disturbances), caution advised; avoid if possible, especially in preterm infants. |
| Teratogenic Risk | First trimester: Limited human data; potential for fetal bradycardia and hypotension. Second and third trimesters: Increased risk of fetal hypotension, renal dysfunction, oligohydramnios, and skull ossification delays. |
| Fetal Monitoring |
■ FDA Black Box Warning
Not applicable
| Serious Effects |
["Anuria","Hypersensitivity to hydrochlorothiazide or sulfonamide-derived drugs"]
| Precautions | ["Hypokalemia","Hyperuricemia","Hypomagnesemia","Hypercalcemia","Orthostatic hypotension","Photosensitivity","Systemic lupus erythematosus exacerbation","Sulfonamide allergy cross-sensitivity"] |
Loading safety data…
| Monitor maternal blood pressure, electrolytes, and renal function. Fetal ultrasound for growth and amniotic fluid volume; consider fetal heart rate monitoring. |
| Fertility Effects | No established adverse effects on human fertility; animal studies show no significant impairment. |